Articles tagged with Tumor Growth
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
The special issue explores challenges and opportunities in managing synthetic genomics risks, introducing a common global baseline for nucleic acid synthesis screening. Review articles provide insights into enhancing gene synthesis security and biosecurity practices of synthetic DNA providers.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
Researchers discovered a new way to effectively treat melanoma using nutrients to reactivate suppressed metabolic pathways in cancer cells. The innovative treatment, involving tyrosine nanomicelles, showed promising results in mice and lab-derived human cells, inhibiting tumour growth and reducing glycolysis.
Researchers found that metformin increases levels of microRNAs miR-2110 and miR-132-3p, targeting genes PIK3R3 and STMN1 to slow down cancer cell growth and division. This study provides new insights into metformin's molecular mechanisms and its potential as a preventive agent for reducing cancer growth.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
A recent study from the Women's Health Initiative found that both obesity and metabolic syndrome increase breast cancer risk, but in distinct ways for different subtypes. The research highlights the importance of controlling waist circumference and metabolic conditions to reduce breast cancer risk.
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
Scientists discover Epstein-Barr virus alters gene regulation in nasopharyngeal cancer cells, leading to rapid tumour growth. The study offers new insights into the link between EBV and NPC, shedding light on intricate processes underlying disease progression.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
A study has shown that a potassium ion channel located in mitochondria rewires metabolism in breast cancer cells, promoting tumor growth. The channel, BKCa, is linked to the Warburg effect, a metabolic hallmark of cancer, by causing increased lactate secretion and hydrogen peroxide levels.
A study led by Washington State University scientists found that inhibiting CDK7 could help prevent heart damage associated with doxorubicin, a commonly used cancer chemotherapy medication. The researchers also discovered that CDK7 inhibition enhances the medication's cancer-killing capability.
A stepped-care model integrating palliative care at key points in patients' cancer trajectories shows reduced palliative care visits without compromising quality of life. The approach enables more efficient delivery of early palliative care, enhancing patient-reported outcomes.
A breakthrough discovery by Nara Institute of Science and Technology researchers identifies EPHA2 as a critical surface protein for preserving stem cell potency. This finding holds promise for safer regenerative medicine by reducing the risk of tumorigenesis, paving the way for organ repair and treatment of degenerative conditions.
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Scientists at Sanford Burnham Prebys and Vanderbilt University have identified phosphatidylinositol-5-phosphate 4-kinases (PI5P4Ks) as a key regulator of the hippo pathway, which is dysregulated in cancer. The study suggests that targeting PI5P4Ks may lead to new treatments for cancers with abnormal hippo signaling.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Researchers found that middle fossa craniotomy significantly improved hearing preservation and quality of life for patients after removing an acoustic neuroma. The study showed excellent facial nerve outcomes in 94% of patients, while 68% preserved their hearing.
Researchers at Ben-Gurion University have discovered a molecular mechanism that enables cancer cells to survive under glucose starvation. By targeting this pathway, they aim to develop a molecule that can block the survival of tumor cells while leaving healthy cells unaffected.
Adult carriers of BAP1 tumor predisposition syndrome show a high incidence of onychopapillomas, a benign nail tumor. This finding suggests using these skin abnormalities to identify family members and patients with cancers associated with the syndrome.
Researchers have developed a new method to detect malignant melanoma using a microneedle patch that measures tyrosinase enzyme levels in the skin. This non-invasive technique has the potential to provide faster and more reliable results compared to traditional biopsies.
The Academic Payvider model enhances value-based care by fostering improved coordination, reduced insurance hassles, and increased staff attention. This joint approach between payers and providers aims to drive complex care down through innovative reimbursement structures.
Researchers found that UTIs can provoke structural changes in breast tissue in mice, which are reversible once the infections are resolved. The study suggests a possible link between UTIs and abnormal breast cell growth, highlighting the importance of considering everyday occurrences on women's well-being.
The study, published in Cell Stem Cell, improves the growth of nephron progenitor cells (NPCs) using a chemical cocktail, enabling sustained growth in a simple 2-dimensional format. The breakthrough has potential for advancing kidney research and discovering new treatments.
Researchers found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer. Mice given a diet rich in vitamin D had better immune resistance to experimentally transplanted cancers and improved responses to immunotherapy treatment.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
A study by researchers at Washington University School of Medicine has found that a drug used to treat epilepsy can prevent brain tumor formation and growth in mice with neurofibromatosis type 1 (NF1). The drug, lamotrigine, was shown to be effective at lower doses than those used for epilepsy, and its effects were lasting. The finding...
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers at the University of Cincinnati Cancer Center presented abstracts on new potential drugs and targets for treating various types of cancer. A study found that a brain-permeable drug called AM-101 sensitizes brain metastatic tumors to radiation, improving survival in preclinical animal models.
Scientists at the University of California San Diego have identified a biochemical pathway that continually surveils mitosis timing and eliminates potentially problematic cells. The 'stopwatch' mechanism uses protein p53 to track cell division time, labeling sequentially delayed divisions as risky.
A team of researchers from Kyoto University has developed a microfluidic co-culture vasculature chip that mimics the microenvironment of alveolar soft part sarcoma (ASPS), a rare cancer. The chip enables scientists to study cell-to-cell interactions and angiogenic mechanisms, which may lead to new strategies for treating ASPS patients.
Scientists from UC3M and Johns Hopkins University have developed a computational model that simulates the invasion process of cancer cells based on the characteristics of surrounding tissue and cell junctions. The model allows for predicting tumor evolution in patients by analyzing mechanical properties of the microenvironment.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
A new study has discovered that Streptococcus anginosus bacteria play a significant role in causing stomach cancer. The research showed that S. anginosus infection led to gastric inflammation, cell damage, and the growth of stomach cancer cells, doubling tumour size and weight in some cases.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Research by Johns Hopkins Medicine suggests that increased stiffness in aging skin contributes to higher rates of melanoma metastasis by stimulating blood vessel growth and making them leaky. Treating older mice with drugs blocking ICAM1 prevented these changes, shrinking tumors and reducing metastasis.
Researchers at the University of Southern Denmark have discovered a new function of the MYC protein, which plays a crucial role in cancer cell growth and division. The study shows that MYC can activate genes on both promoters and enhancers, driving cancer progression.
Researchers at the University of Cincinnati Cancer Center have identified a new protein called p47 that helps prevent breast cancer metastasis. The study found that lower p47 expression was correlated with higher breast cancer metastasis, and that increasing p47 function could potentially lead to new therapies.
A recent study at Salk Institute evaluates the reliability of patient-derived organoids as a clinical model for pancreatic cancer. The findings reveal that organoids' gene expression and drug responses are not affected by commercial extracellular matrix brands, but one product increases growth rate.
A study published in Cancer Research Communications reveals a potential genetic marker associated with better survival outcomes in patients with head and neck cancer. The researchers found that the presence of a specific genetic variant and higher expression of the GAN gene product gigaxonin may contribute to improved survival rates.
A study by UC San Francisco researchers found that daily cannabis users had a 25% increased risk of heart attack and a 42% increased risk of stroke compared to non-users. The study also found significant cardiovascular risks associated with cannabis use, including coronary heart disease and the combination of heart attack and stroke.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers found that cancer reprograms neutrophils to promote tumour growth, enabling targeted therapeutic approaches. By understanding this process, scientists can develop new treatments to block tumour growth and improve clinical outcomes for cancer patients.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
New research led by Johns Hopkins Medicine reveals that age-related changes in fibroblast cells enable pancreatic cancer tumor growth. The study found that older patients have poorer prognoses due to altered proteins released by fibroblasts, which promote cancer cell growth and spread.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Researchers discovered that blocking efferocytosis pathway prevents immunosuppressive activity in macrophages, restoring T cell activation and reducing metastatic tumour burden. The study found PDAC metastases to show high levels of immunosuppressive macrophages, promoting tumour growth.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
Researchers have developed a new approach to treating cutaneous neurofibromas, a common skin tumor associated with neurofibromatosis type 1. By targeting the cAMP and Ras/MAPK pathways, this combination therapy may provide an enduring halt in the expansion of these tumors.
Researchers at Duke University have discovered how stem cells decide their fate by analyzing the activity of two key regulators, short-root and scarecrow, in real-time using light sheet microscopy. This finding has implications for understanding cell development and preventing diseases such as cancer.
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.